Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Cadila Healthcare Ltd    CADILAHC   INE010B01027

CADILA HEALTHCARE LTD (CADILAHC)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Cadila Healthcare : gets Mexico regulator approval for Lipaglyn

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:58pm CEST

Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. Zydus today announced that the Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval to commercialize Lipagly (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.

Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).

"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia", said Pankaj Patel, Chairman, Zydus Group, and added, "This approval of Saroglitazar in Mexico is a major milestone for the company."

Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. The scrip opened at Rs 476 and has touched a high and low of Rs 478 and Rs 464.5 respectively.

(c) 2017India Infoline Ltd. All rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CADILA HEALTHCARE LTD
06/14CADILA HEALTHCARE : Patent Issued for Crystalline Form of Rifaximin and Process ..
AQ
06/05CADILA HEALTHCARE : rises 2% on USFDA approval to antibiotic drug
AQ
05/29CADILA HEALTHCARE : stock drops 4%
AQ
05/28CADILA HEALTHCARE : stock drops 4%
AQ
05/26CADILA HEALTHCARE : Zydus Cadila gets USFDA nod for prostate condition treatment..
AQ
05/26CADILA HEALTHCARE LTD'S Q4FY18 CONSO : Beats Estimates
AQ
05/25CADILA HEALTHCARE : announces ANDA approval ahead of Q4 numbers
AQ
05/22CADILA HEALTHCARE LTD : annual earnings release
05/03CADILA HEALTHCARE : Patent Issued for Polymorphic Form of Pyrrole Derivative and..
AQ
04/28CADILA HEALTHCARE : SELLS 50% OF ITS STAKE IN BAYER-ZYDUS JVs
AQ
More news
Financials ( INR)
Sales 2019 128 B
EBIT 2019 23 880 M
Net income 2019 19 505 M
Debt 2019 18 630 M
Yield 2019 0,96%
P/E ratio 2019 20,92
P/E ratio 2020 18,24
EV / Sales 2019 3,35x
EV / Sales 2020 3,02x
Capitalization 410 B
Chart CADILA HEALTHCARE LTD
Duration : Period :
Cadila Healthcare Ltd Technical Analysis Chart | CADILAHC | INE010B01027 | 4-Traders
Technical analysis trends CADILA HEALTHCARE LTD
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 38
Average target price 446  INR
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Sharvil Pankajbhai Patel Joint Managing Director & Executive Director
Pankaj Ramanbhai Patel Executive Chairman & Joint Managing Director
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Humayun Raja Dhanrajgir Independent Non-Executive Director
Sector and Competitors